A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2004
12/08/2004	EP1482791A1 Antimicrobial therapeutic compositions and methods of use
12/08/2004	EP1434886A4 Mid 241 receptor, a novel g-protein coupled receptor
12/08/2004	EP1303290A4 Small peptides and methods for downregulation of ige
12/08/2004	EP1233787B1 Product inhibiting transduction of g heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment
12/08/2004	EP1210118B1 Composition comprising a tramadol material and an anticonvulsant drug
12/08/2004	EP1141014B1 Insulin-like growth factor (igf) i mutant variant
12/08/2004	EP1121354B1 N-(imidazolylalkyl)substituted cyclic amines as histamine-h 3 agonists or antagonists
12/08/2004	EP0812190B1 R-enantiomer of n-propargyl-1-aminoindan for the treatment of various diseases and mesylate, esylate and sulfate thereof
12/08/2004	EP0801570B1 Formulations and methods for reducing skin irritation
12/08/2004	CN1554026A Prognostic indicator
12/08/2004	CN1553958A Photochemical internalization for delivery of molecules into the cytosol
12/08/2004	CN1553952A Materials and methods to promote repair of nerve tissue
12/08/2004	CN1553813A Complement pathway inhibitors binding to C5 and C5A without preventing formation of C5B
12/08/2004	CN1553806A Use of SAPR-1 for the treatment and/or prevention of scleroderma
12/08/2004	CN1553804A Combinations for the treatment of inflammatory disorders
12/08/2004	CN1553803A Use of 4-pyridylmethylphthalazines for cancer treatment
12/08/2004	CN1553797A Carboxylate-gated-nitroxide (CGN) compounds and compositions and methods of use thereof
12/08/2004	CN1553794A Stable skin conditioning compositions containing retinoid boosters
12/08/2004	CN1178912C Small molecule inhibitors of rotamase enzyme activity
12/08/2004	CN1178696C Preparation for treatment of metabolic syndrome containing human growth hormone in combination with cortisol synthesis inhibitor
12/08/2004	CN1178663C Use of 1,4-benzothiazepine derivatives as drugs overcoming carcinostatic tolerance
12/08/2004	CN1178657C Treatment and prophylaxis of pancreatitis
12/07/2004	US6828430 For prognosis/treatment; poly(A) binding protein II (PAB II)
12/07/2004	US6828343 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
12/07/2004	US6828341 Brain disorders; anticonvulsants; central nervous system disorders; psychological disorders
12/07/2004	US6828340 Especially for cancer which has developed a multidrug-resistant phenotype.
12/07/2004	US6828338 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
12/07/2004	US6828335 Oxazole or thiazole-ethyl-oxy-indane acetic acid derivatives; useful for the treatment of diseases such as diabetes, obesity, hyperlipidemia and atherosclerosis
12/07/2004	US6828334 Having high dissolution profile and in vivo enhanced bioavailability
12/07/2004	US6828312 Therapy of mammal susceptible to, suffering from, suspected of having or recovering from a disease impacted by tissue factor(TF), by administering TF blocking compound
12/07/2004	US6828298 Glycoprotein having inhibitory activity against helicobacter pylori colonization
12/07/2004	US6828297 For therapy of diabetes
12/07/2004	US6827951 Composition and method for smoke detoxification
12/07/2004	US6827947 Film coating
12/07/2004	US6827946 Compositions containing both sedative and non-sedative antihistamines
12/07/2004	US6827932 Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages
12/07/2004	CA2208673C Composition for inhibiting intimal hyperplasia using pdgf antagonists and heparin
12/02/2004	WO2004104200A1 Method of controlling cell proliferation by using novel function of myeloid leukemia factor mlf1 and utilization of the same
12/02/2004	WO2004103410A1 Methods compositions and articles of manufacture for modulating bone growth
12/02/2004	WO2004103408A2 Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine
12/02/2004	WO2004103407A2 Composition comprising a pde4 inhibitor and a pde5 inhibitor
12/02/2004	WO2004103383A1 A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein
12/02/2004	WO2004103377A1 Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain
12/02/2004	WO2004103369A1 Pharmaceutical composition containing histone deacetylase inhibitor
12/02/2004	WO2004103365A1 Antiarthritic combinations
12/02/2004	WO2004103359A1 Pharmaceutical combination comprising modafinil and another drug
12/02/2004	WO2004103358A2 Combination of histone deacetylase inhibitors with chemotherapeutic agents
12/02/2004	WO2004103357A1 Compositions for the treatment of reduced blood flow
12/02/2004	WO2004103355A1 Method for augmenting the antitumor activity of anti-cancer agents
12/02/2004	WO2004103346A1 Pharmaceutical compositions of acitretin
12/02/2004	WO2004103344A1 Combination chemotherapy comprising a liposomal platinum complex
12/02/2004	WO2004103336A2 Drug delivery system
12/02/2004	WO2004103333A1 Tissue culture media used as a component of cosmetics
12/02/2004	WO2004103311A2 Antibiotic composition
12/02/2004	WO2004103274A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
12/02/2004	WO2004103271A2 Disease prevention and vaccination prior to thymic reactivations
12/02/2004	WO2004103263A2 Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
12/02/2004	WO2004103233A1 Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde
12/02/2004	WO2004080393A3 Selective cytokine inhibitory drugs for treating disorders of the central nervous system
12/02/2004	WO2004071431A3 Method and composition for treating neurodegenerative disorders
12/02/2004	WO2004060321A3 Cardioprotective delta opioid receptor agonists and methods of using same
12/02/2004	WO2004060284A3 Method of using colloidal metal-protein composition for treatment of cancer
12/02/2004	WO2004050027A3 Materials and methods for treating ocular-related disorders
12/02/2004	WO2004041191A3 Methods for the treatment, prevention and management of macular degeneration
12/02/2004	WO2004027020A3 Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis
12/02/2004	WO2003104256A3 THE CaR RECEPTOR AS A MEDIATOR OF MIGRATORY CELL CHEMOTAXIS AND/OR CHEMOKINESIS
12/02/2004	WO2003095667A3 Autoimmune conditions and nadph oxidase defects
12/02/2004	WO2003085377A3 Novel pancortin-pablo protein interactions and methods of use thereof
12/02/2004	WO2003078465A8 The use of an epitope of vascular endothelial growth factor receptor kdr/flk-1
12/02/2004	WO2003039452A3 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
12/02/2004	WO2002051981A3 Defects in periaxin associated with myelinopathies
12/02/2004	US20040243606 Hormonal contraceptive product
12/02/2004	US20040243316 Crystallographic structure of the androgen receptor ligand binding domain
12/02/2004	US20040243097 Antiproliferative drug and delivery device
12/02/2004	US20040242904 Novel sordarin derivative isolated from culture fermentations and functions as an antifungal agent
12/02/2004	US20040242698 Analeptic and antidepressant combinations
12/02/2004	US20040242682 Compositions comprising arginine and nitrates
12/02/2004	US20040242677 Treatment of osteoporosis and autoimmune disease with astrogorgiadiol
12/02/2004	US20040242675 Compositions useful for the treatment of pathologies responding to the activation of PPAR-gamma receptor
12/02/2004	US20040242660 Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders
12/02/2004	US20040242658 Recrystallizing rosiglitazone maleate from solvent; for treatment or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and complication thereof in a mammal
12/02/2004	US20040242651 to gastrointestal systems, kidneys
12/02/2004	US20040242647 Use of organic compounds
12/02/2004	US20040242638 Treatment of rhinitis with steroids as antiallergens
12/02/2004	US20040242632 Method for treating inflammatory bowel disease
12/02/2004	US20040242629 Quinuclidine carbamate derivatives and their use as M3 antagonists
12/02/2004	US20040242626 Nasal delivery of apomorphine
12/02/2004	US20040242625 Nasal delivery of apomorphine
12/02/2004	US20040242624 Nasal delivery of apomorphine
12/02/2004	US20040242612 Use of tyrosine kinase inhibitors for promoting hair growth
12/02/2004	US20040242602 Novel thiazolidine compounds as calcium sensing receptor modulators
12/02/2004	US20040242601 Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
12/02/2004	US20040242597 Combination
12/02/2004	US20040242588 alpha 2 adrenergic receptor agonist in a topical carrier; amount sufficient to decrease blood flow through the small arteries or arterioles of the skin of the patient
12/02/2004	US20040242567 alone or in combination with a diuretic agent; diabetic nephropathy
12/02/2004	US20040242565 Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy
12/02/2004	US20040242564 1,2,3,4-tetrahydroisoquinolines derivatives
12/02/2004	US20040242552 New use of antimineralocorticoid compounds against narcotic withdrawal syndrome
12/02/2004	US20040242551 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
12/02/2004	US20040242524 A synergistic combination of an anitcarcinogenic agent and Mycobacterium phlei-DNA (M-DNA) preserved and complexed on M. phlei cell wall (MCC); improved cell proliferation inhibition

1 ... 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 ... 1151